Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een fase III-studie van HMPL-760 in combinatie met R-GemOx versus placebo in combinatie met R-GemOx bij recidiverend/refractair DLBCL

9 november 2026 bijgewerkt door: Hutchmed

Een fase III gerandomiseerde, dubbelblinde, positief gecontroleerde studie om de werkzaamheid, veiligheid en farmacokinetiek van HMPL-760 in combinatie met R-GemOx te evalueren versus placebo in combinatie met R-GemOx bij patiënten met recidiverend/refractair diffuus grootcellig B-cellymfoom (DLBCL)

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

Studietype

Ingrijpend

Inschrijving (Geschat)

240

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Baoding, China
        • Werving
        • Baoding NO.1 Central Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Haiying Yao
      • Beijing, China
        • Werving
        • Beijing GoBroad Hospital
        • Hoofdonderzoeker:
          • Kai Hu
        • Contact:
      • Beijing, China
        • Werving
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • Hoofdonderzoeker:
          • Liang Wang
        • Contact:
      • Bengbu, China
        • Werving
        • The First Affiliated Hospital of Bengbu Medical College
        • Contact:
        • Hoofdonderzoeker:
          • Yanli Yang
      • Changchun, China
        • Werving
        • The First Hospital of Jilin University
        • Hoofdonderzoeker:
          • Ou Bai
        • Contact:
      • Changsha, China
        • Werving
        • Hunan Cancer Hospital
        • Hoofdonderzoeker:
          • Hui Zhou
        • Contact:
      • Changsha, China
        • Werving
        • The Second Xiangya Hospital of Central South University
        • Hoofdonderzoeker:
          • Hongling Peng
        • Contact:
      • Changsha, China
        • Werving
        • People's Hospital of Hunan Province
        • Contact:
        • Hoofdonderzoeker:
          • Can Liu
      • Chengdu, China
        • Werving
        • West China Hospital of Sichuan University
        • Hoofdonderzoeker:
          • Liqun Zou
        • Contact:
      • Chengdu, China
        • Werving
        • Sichuan Provincial People's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Xiaobing Huang
      • Chongqing, China
        • Werving
        • The First Affiliated Hospital of Chongqing Medical University
        • Hoofdonderzoeker:
          • Xin Wang
        • Contact:
      • Chongqing, China
        • Werving
        • Chongqing University Cancer Hospital
        • Hoofdonderzoeker:
          • Yao Liu
        • Contact:
      • Fujian, China
        • Werving
        • Quanzhou First Hospital.Fujian
        • Contact:
        • Hoofdonderzoeker:
          • Xiongpeng Zhu
      • Fuzhou, China
        • Werving
        • Fujian Medical University Union Hospital
        • Hoofdonderzoeker:
          • Jianzhen Shen
        • Contact:
      • Guangzhou, China
        • Werving
        • Sun Yat-sen University Cancer Center
        • Hoofdonderzoeker:
          • Zhiming Li
        • Contact:
      • Guangzhou, China
        • Werving
        • Guangdong Provincial People's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Xiaojuan Wei
      • Guangzhou, China
        • Werving
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • Hoofdonderzoeker:
          • Yuhua Li
        • Contact:
      • Guiyang, China
        • Werving
        • The Affiliated Hospital of Guizhou Medical University
        • Hoofdonderzoeker:
          • Yan Zhang
        • Contact:
      • Hangzhou, China
        • Werving
        • Zhejiang Cancer Hospital
        • Hoofdonderzoeker:
          • Haiyan Yang
        • Contact:
      • Hangzhou, China
        • Werving
        • The First Affiliated Hospital, Zhejiang University
        • Hoofdonderzoeker:
          • Zhen Cai
        • Contact:
      • Harbin, China
        • Werving
        • Harbin Medical University Cancer Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Qingyuan Zhang
      • Hefei, China
        • Werving
        • The Second Affiliated Hospital of Anhui Medical University
        • Contact:
        • Hoofdonderzoeker:
          • Zhimin Zhai
      • Jinan, China
        • Werving
        • Qilu Hospital of Shandong University
        • Contact:
        • Hoofdonderzoeker:
          • Shuqian Xu
      • Jinan, China
        • Werving
        • Shandong Cancer Hospital & Institute
        • Hoofdonderzoeker:
          • Zengjun Li
        • Contact:
      • Kunming, China
        • Nog niet aan het werven
        • The First Affiliated Hospital of Kunming Medical University
        • Contact:
        • Hoofdonderzoeker:
          • Mingxia Shi
      • Nanchang, China
        • Werving
        • Jiangxi Cancer Hospital
        • Hoofdonderzoeker:
          • Yan Huang
        • Contact:
      • Nanjing, China
        • Werving
        • Jiangsu Cancer Hospital
        • Hoofdonderzoeker:
          • Yan Zhang
        • Contact:
      • Nanjing, China
        • Werving
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • Contact:
        • Hoofdonderzoeker:
          • Jingyan Xu
      • Nanning, China
        • Werving
        • The First Affiliated Hospital of Guangxi Medical University
        • Hoofdonderzoeker:
          • Zhigang Peng
        • Contact:
      • Qingdao, China
        • Werving
        • The Affiliated Hospital of Qingdao University
        • Contact:
        • Hoofdonderzoeker:
          • Xia Zhao
      • Shanghai, China
        • Werving
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Hoofdonderzoeker:
          • Weili Zhao
        • Contact:
      • Shanghai, China
        • Werving
        • Tongji Hospital of Tongji University
        • Contact:
        • Hoofdonderzoeker:
          • Ping Li
      • Shanghai, China
        • Nog niet aan het werven
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • Hoofdonderzoeker:
          • Ligen Liu
        • Contact:
      • Shenyang, China
        • Werving
        • Shengjing Hospital of China Medical University
        • Hoofdonderzoeker:
          • Wei Yang
        • Contact:
      • Shenzhen, China
        • Werving
        • Shenzhen people's hospital
        • Hoofdonderzoeker:
          • Jihao Zhou
        • Contact:
      • Taiyuan, China
        • Werving
        • Shanxi Provincial Cancer Hospital
        • Hoofdonderzoeker:
          • Liping Su
        • Contact:
      • Tangshan, China
        • Werving
        • North China University of Science and Technology Affiliated Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Zhenyu Yan
      • Tianjin, China
        • Werving
        • Tianjin Medical University Cancer Institute & Hospital
        • Hoofdonderzoeker:
          • Zhengzi Qian
        • Contact:
          • Zhengzi Qian
          • Telefoonnummer: 13702031222
          • E-mail: qzz@163.com
      • Tianjin, China
        • Werving
        • Tianjin People's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Xingli Zhao
      • Tianjin, China
        • Werving
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • Hoofdonderzoeker:
          • Dehui Zou
        • Contact:
      • Wenzhou, China
        • Werving
        • The First Affiliated Hospital of WMU
        • Contact:
        • Hoofdonderzoeker:
          • Songfu Jiang
      • Wuhan, China
        • Werving
        • Hubei Cancer Hospital
        • Hoofdonderzoeker:
          • Huijing Wu
        • Contact:
      • Wuhan, China
        • Werving
        • Wuhan Union Hospital of China
        • Hoofdonderzoeker:
          • Liling Zhang
        • Contact:
      • Xi'an, China
        • Werving
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Hoofdonderzoeker:
          • Pengcheng He
        • Contact:
      • Xi'an, China
        • Werving
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • Hoofdonderzoeker:
          • Jie Liu
        • Contact:
      • Xiamen, China
        • Nog niet aan het werven
        • The First Affiliated Hospital of Xiamen University
        • Hoofdonderzoeker:
          • Bing Xu
        • Contact:
      • Xuzhou, China
        • Werving
        • The Affiliated Hospital of Xuzhou Medical University
        • Contact:
        • Hoofdonderzoeker:
          • Wei Sang
      • Zhengzhou, China
        • Werving
        • Henan Cancer Hospital
        • Hoofdonderzoeker:
          • Keshu Zhou
        • Contact:
      • Zhengzhou, China
        • Werving
        • The First Affiliated Hospital of Zhengzhou University
        • Contact:
        • Hoofdonderzoeker:
          • Xudong Zhang
      • Ürümqi, China
        • Werving
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Hoofdonderzoeker:
          • Yan Li
        • Contact:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Werving
        • Fudan University Shanghai Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Fangfang Lv

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Andere namen:
  • Gemcitabine Hydrochloride voor injectie
  • Rituximab-injectie
  • Oxaliplatin-injectie
Placebo-vergelijker: The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Andere namen:
  • Gemcitabine Hydrochloride voor injectie
  • Rituximab-injectie
  • Oxaliplatin-injectie

Patients will receive HMPL-760 placebo once daily (QD) orally.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-free survival (PFS)
Tijdsspanne: Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
Tijdsspanne: Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
Tijdsspanne: Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
Tijdsspanne: Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
Tijdsspanne: Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
Tijdsspanne: Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Independent review committee (IRC)-assessed PFS
Tijdsspanne: Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
Tijdsspanne: Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
Tijdsspanne: Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
Tijdsspanne: Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
Tijdsspanne: Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
Tijdsspanne: Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
Tijdsspanne: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Tijdsspanne: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Biomarker assessment
Tijdsspanne: Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Tijdsspanne: Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tijdsspanne: Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tijdsspanne: Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tijdsspanne: Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tijdsspanne: Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tijdsspanne: Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Weili Zhao, Ruijin Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 maart 2026

Primaire voltooiing (Geschat)

30 april 2028

Studie voltooiing (Geschat)

30 december 2028

Studieregistratiedata

Eerst ingediend

28 januari 2026

Eerst ingediend dat voldeed aan de QC-criteria

6 februari 2026

Eerst geplaatst (Werkelijk)

13 februari 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .